Foghorn Therapeutics Inc. (FHTX) vs Lucid Diagnostics Inc. (LUCD)
A side-by-side comparison of Foghorn Therapeutics Inc. and Lucid Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FHTX
Foghorn Therapeutics Inc.
$1.93HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
LUCD
Lucid Diagnostics Inc.
$0.60HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — FHTX vs LUCD
growth of $100 · dividends reinvested · last 5yFHTX -83.5% (-30.2%/yr)LUCD -95.0% (-45.0%/yr)FHTX compounded faster over this window
FHTX LUCD
FHTX vs LUCD: by the numbers
- •LUCD is the larger company ($115M vs $113M market cap).
- •Both run net losses; FHTX's is the smaller (-175.78% vs -959.76% net margin).
Metrics side by side
Valuation
| Metric | FHTX | LUCD |
|---|---|---|
| P/S ratio | 3.08 | 21.14 |
| P/B ratio | N/A | 10.53 |
Profitability
| Metric | FHTX | LUCD |
|---|---|---|
| Gross margin | 89.22% | -60.26% |
| Operating margin | -265.64% | -1054.82% |
| Net margin | -175.78% | -959.76% |
| ROE | N/A | -478.26% |
| ROIC | -44.81% | -145.10% |
Growth (annualized)
| Metric | FHTX | LUCD |
|---|---|---|
| Revenue CAGR (5Y) | 105.83% | N/A |
| Total return CAGR (5Y) | -31.87% | N/A |
Go deeper
Dig into the metrics
Foghorn Therapeutics ROELucid Diagnostics ROEFoghorn Therapeutics operating marginLucid Diagnostics operating marginFoghorn Therapeutics revenue growthLucid Diagnostics revenue growthFoghorn Therapeutics free cash flowLucid Diagnostics free cash flow
Foghorn Therapeutics & Lucid Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.